MedTrace Logo

Effects of Dry Needling on Vertical Jump Performance

NCT06184672 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2024-01-26

No results posted yet for this study

Summary

ChatGPT ChatGPT Injury prevention and performance enhancement have become two of the main goals in every sport. Myofascial Pain Syndrome is primarily caused by myofascial trigger points, which may result in referred pain, stiffness, shortening, and/or muscle weakness.

The aim of this study is to assess the effects of dry needling on latent myofascial trigger points (LTMTP) and its impact on vertical jump height in female volleyball players.

The study is a single-blind, randomized controlled clinical trial conducted on healthy female volleyball practitioners with no lower limb injuries in the last 6 months. Participants must exhibit LMTP in the triceps surae muscles and be familiar with the counter-movement jump (CMJ) test. Subjects will be randomly assigned to either a control group or an intervention group.

Conditions

  • Sports Physical Therapy

Interventions

OTHER

dry needling

the area is disinfected by the use of 0.5% chlorhexidine digluconate alcohol solution. The physiotherapist in charge of the intervention uses sterile nitrile gloves, using dry needling needles with dimensions of 0.30 x 50 mm is used. This technique, designed by Hong, applies speed both at the entrance, in order to provoke the local spasm response and at the exit. The inputs and outputs are performed until the REL disappears or until the tolerance threshold of the patient is reached. Immediately after performing the puncture, ischemic compression is performed on the treated muscle, in order to decrease the duration and intensity of post-puncture pain. For this, a digital pressure is made to the point where the patient's sensation ceases to be pressure and becomes pain. Once the patient is noted that pain is repeated again the art up to a total of 2 minutes

Sponsors & Collaborators

  • Universidad Europea de Madrid

    collaborator OTHER

  • Sierra Varona SL

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
25 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-02-08
Primary Completion
2024-02-29
Completion
2024-03-12

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06184672 on ClinicalTrials.gov